Medicatieveiligheid
Optimizing therapy in patients suffering from statin-intolerance: n=1 trials.
- Universiteit Erasmus Medisch Centrum Rotterdam
- Promovendus Ruben Mijnster
- Promoters Hugo van der Kuy
- Co-Promoters Melvin Lafeber Jeanine Roeters-van Lennep
- Jaar 2024-2028
My research focuses on the occurence of nocebo-effects in statin-intolerant. We try to identify patients who are statin-intolerant and that suffer from these effects. We hope that by identifying patients affected by the nocebo effect and allowing them to experientially understand its impact through an N=1 study design, they will experience fewer side effects from their statin treatment. This may help prevent the need to switch to expensive PCSK9 inhibitors.